NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

體外診斷 (IVD)的全球市場 (各產品/服務,各技術,各用途,各終端用戶):產業分析、成長預測 (到2030年)

In Vitro Diagnostic Market Research Report: By Offering, Technology, Application, End User - Global Industry Analysis and Growth Forecast to 2030

出版商 Prescient & Strategic Intelligence Private Limited 商品編碼 975721
出版日期 內容資訊 英文 344 Pages
商品交期: 2-3個工作天內
價格
體外診斷 (IVD)的全球市場 (各產品/服務,各技術,各用途,各終端用戶):產業分析、成長預測 (到2030年) In Vitro Diagnostic Market Research Report: By Offering, Technology, Application, End User - Global Industry Analysis and Growth Forecast to 2030
出版日期: 2020年10月01日內容資訊: 英文 344 Pages
簡介

全球體外診斷 (IVD)的市場規模,2019年是635億美元,預計2030年達1274億美元,以6.6%的年複合成長率擴大。市場主要促進因素,是血液樣品的污染相關法規強化的動向,及慢性疾病的發病率上升,捐血者的增加,IVD技術迅速的進步,教育機關、醫院的增加,世界各國的醫療費增加等。各地區中,在亞太地區各國預計市場大幅度成長。

本報告提供全球體外診斷 (IVD)的市場相關分析,技術的概要和背景情況,市場基本結構和主要的推動及阻礙市場要素,市場規模的成果值、預測值 (今後11年份),各產品/服務、各技術、各用途、各終端用戶、各地區的詳細趨勢,市場競爭狀態,主要企業簡介等調查。

目錄

第1章 分析的背景情況

第2章 分析方法

第3章 摘要整理

第4章 簡介

  • 市場區隔定義
    • 各產品/服務
      • 試劑、套件
      • 診斷設備
      • 軟體、服務
    • 各技術
      • 臨床化學
      • 免疫化學
      • 分子診斷
      • 血液檢驗
      • 其他
    • 各用途
      • 感染疾病
      • 糖尿病
      • 腫瘤
      • 心臟病
      • 腎臟疾病
      • 自體免疫疾病
      • 其他
    • 各終端用戶
      • 醫院、診療所
      • POC (照護現場)
      • 研究、教育機關
  • 價值鏈分析
  • 市場動態
    • 市場趨勢
      • 新產品的認證與發售
      • 事業聯盟、契約的數量增加
    • 促進因素
      • 血液的安全性與樣品污染相關法規
      • 慢性病患的負擔劇增
      • 捐血者的增加
      • IVD的技術進步
      • 醫療費的增加
      • 醫院、教育機關的增加
      • 對市場預測的促進因素的影響分析
    • 阻礙因素
      • 在維持充分安全的樣品供給上的課題
      • 對捐贈者的人口統計資訊的資料不穩定性
      • IVD產品的成本效益
      • 對市場預測的阻礙因素的影響分析
  • 波特的五力分析
  • 新型冠狀病毒感染疾病 (COVID-19)的影響

第5章 全球市場:市場規模與其預測

  • 各產品/服務
  • 各技術
    • 臨床化學
    • 免疫化學
    • 分子診斷
    • 血液檢驗
  • 各用途
  • 各終端用戶
  • 各地區

第6章 北美市場:市場規模與其預測

  • 各產品/服務
  • 各技術
  • 各用途
  • 各終端用戶
  • 各國
    • 美國市場
    • 加拿大市場

第7章 歐洲市場:市場規模與其預測

  • 各國
    • 德國市場
    • 法國市場
    • 義大利市場
    • 西班牙市場
    • 英國市場

第8章 亞太地區市場:市場規模與其預測

  • 各國
    • 中國市場
    • 日本市場
    • 印度市場

第9章 南美市場:市場規模與其預測

  • 各國
    • 巴西市場
    • 墨西哥市場

第10章 中東、非洲市場:市場規模與其預測

  • 各國
    • 沙烏地阿拉伯市場
    • 南非市場

第11章 競爭情形

  • 主要企業的市場佔有率
  • 主要企業的策略展開情形
    • 產品的銷售、核准
    • 企業合併、收購 (M&A)
    • 其他

第12章 企業簡介

  • Thermo Fisher Scientific Inc.
    • 產業概要
    • 主要產品/服務
    • 主要的財務指標
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • PerkinElmer Inc.
  • Quidel Corporation
  • OraSure Technologies Inc.
  • Sysmex Corporation
  • DIAGNOSTICA STAGO S.A.S
  • Siemens AG
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Hologic Inc.
  • Sartorius Stedim Biotech S.A.
  • Bio-Rad Laboratories Inc.
  • bioMerieux S.A.
  • Trinity Biotech plc
  • Bio-Techne Corporation
  • DiaSorin S.p.A.
  • Ortho-Clinical Diagnostics Inc.
  • Grifols S.A.

第13章 附錄

目錄
Product Code: LS10210

Title:
In Vitro Diagnostic Market Research Report: By Offering (Reagents & Kits, Instruments, Software & Services), Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics, Hematology, Microbiology), Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases), End User (Hospitals & Clinics, Point of Care, Laboratories, Research & Academic Institutes) - Global Industry Analysis and Growth Forecast to 2030.

The global in-vitro diagnostic (IVD) market reached a valuation of $63.5 billion in 2019 and is predicted to progress at a CAGR of 6.6% between 2020 and 2030. According to the estimates of P&S Intelligence, a market research firm based in India, the market would generate a revenue of $127.4 billion by 2030. The key factor driving the progress of the market is the rising enactment of strict regulations and policies in several countries regarding blood sample contamination.

Besides the aforementioned factor, the growing incidence of chronic diseases, the surging number of blood donors, rapid advancements and innovations in the IVD technology, the increasing number of academic institutions and hospitals, and soaring healthcare expenditure in various countries are also fueling the expansion of the in-vitro diagnostic market across the world. As per the International Diabetes Federation (IDF) Atlas 9th edition, 352 million people in the age group 20-64 were diagnosed with diabetes in 2019.

Furthermore, this number is predicted to grow to 486 million by 2045. As per the findings of the World Health Organization (WHO), cancer claimed as many as 9.6 million lives in 2018. The Joint United Nations Programme on HIV/AIDS (UNAIDS) found that 37.9 million people around the world suffered from HIV/AIDS in 2018. The high occurrence of these diseases is boosting the demand for IVD testing, which is, in turn, propelling the growth of the market.

Based on offering, the in-vitro diagnostic market is divided into software & services, instruments, and reagents & kits. Out of these, the reagents & kits category is predicted to dominate the market in the future years. The increasing number of IVD tests being performed all over the world, because of the ballooning prevalence of infectious and chronic diseases and the surging number of research activities, is driving the advancement of this category in the market in the forthcoming years.

Geographically, the in-vitro diagnostic market is predicted to exhibit the fastest growth in the Asia-Pacific (APAC) region in the upcoming years. This would be because of the existence of leading market players in the region and their focus on various strategic development activities in order to improve their market position. For example, according to Abbott Laboratories, in October 2019, the Australian Red Cross Blood Service signed a multi-year agreement for Alinity system, the organization's plasma and blood screening technology.

Hence, it can be said without any hesitation that the market would boom in the future years, primarily because of the increasing requirement for blood donations and the growing enactment of several strict policies regarding blood contamination in several countries around the world.

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Offering
    • 1.3.2 Market Segmentation by Technology
    • 1.3.3 Market Segmentation by Application
    • 1.3.4 Market Segmentation by End User
    • 1.3.5 Market Segmentation by Region
    • 1.3.6 Analysis Period
    • 1.3.7 Market Data Reporting Unit
      • 1.3.7.1 Value
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Definition of Market Segments
    • 4.1.1 By Offering
      • 4.1.1.1 Reagents & kits
      • 4.1.1.2 Instruments
      • 4.1.1.3 Software & services
    • 4.1.2 By Technology
      • 4.1.2.1 Clinical chemistry
        • 4.1.2.1.1 Basic metabolic panel
        • 4.1.2.1.2 Lipid profile
        • 4.1.2.1.3 Liver profile
        • 4.1.2.1.4 Renal profile
        • 4.1.2.1.5 Thyroid function panel
        • 4.1.2.1.6 Others
      • 4.1.2.2 Immunochemistry
        • 4.1.2.2.1 ELISA
        • 4.1.2.2.2 RIA
        • 4.1.2.2.3 FIA
        • 4.1.2.2.4 CLIA
        • 4.1.2.2.5 ICA
        • 4.1.2.2.6 Others
      • 4.1.2.3 Molecular diagnostics
        • 4.1.2.3.1 Infectious diseases
        • 4.1.2.3.2 Genomics
        • 4.1.2.3.3 Blood donor screening
        • 4.1.2.3.4 Others
      • 4.1.2.4 Hematology
        • 4.1.2.4.1 CBC
        • 4.1.2.4.2 Cholesterol testing
        • 4.1.2.4.3 Blood glucose testing
        • 4.1.2.4.4 Hemoglobin testing
        • 4.1.2.4.5 Coagulation testing
        • 4.1.2.4.6 Others
      • 4.1.2.5 Others
    • 4.1.3 By Application
      • 4.1.3.1 Infectious diseases
      • 4.1.3.2 Diabetes
      • 4.1.3.3 Oncology
      • 4.1.3.4 Cardiology
      • 4.1.3.5 Nephrology
      • 4.1.3.6 Autoimmune diseases
      • 4.1.3.7 Others
    • 4.1.4 By End User
      • 4.1.4.1 Hospitals & clinics
      • 4.1.4.2 POC
      • 4.1.4.3 Research & academic institutes
  • 4.2 Market Dynamics
    • 4.2.1 Trends
      • 4.2.1.1 Approval and launch of new products
      • 4.2.1.2 Increasing number of collaborations and agreements
    • 4.2.2 Drivers
      • 4.2.2.1 Regulations with respect to blood safety and sample contamination
      • 4.2.2.2 Surging burden of chronic diseases
      • 4.2.2.3 Increasing number of blood donors
      • 4.2.2.4 Advancements in IVD technology
      • 4.2.2.5 Increasing healthcare expenditure
      • 4.2.2.6 Increasing number of hospitals and academic institutes
      • 4.2.2.7 Impact analysis of drivers on the market forecast period
    • 4.2.3 Restraints
      • 4.2.3.1 Challenges in maintaining sufficient, safe sample supply
      • 4.2.3.2 Data insecurity over donors' demographic information
      • 4.2.3.3 Cost-ineffectiveness of IVD products
      • 4.2.3.4 Impact analysis of restraints on the market forecast
  • 4.3 Porter's Five Forces Analysis
  • 4.4 Impact of COVID-19

Chapter 5. Global Market Size and Forecast

  • 5.1 By Offering
  • 5.2 By Technology
    • 5.2.1 IVD Market for Clinical Chemistry, by Type
    • 5.2.2 IVD Market for Immunochemistry, by Type
    • 5.2.3 IVD Market for Molecular Diagnostics, by Type
    • 5.2.4 IVD Market for Hematology, by Type
  • 5.3 By Application
  • 5.4 By End User
  • 5.5 By Region

Chapter 6. North America Market Size and Forecast

  • 6.1 By Offering
  • 6.2 By Technology
    • 6.2.1 IVD Market for Clinical Chemistry, by Type
    • 6.2.2 IVD Market for Immunochemistry, by Type
    • 6.2.3 IVD Market for Molecular Diagnostics, by Type
    • 6.2.4 IVD Market for Hematology, by Type
  • 6.3 By Application
  • 6.4 By End User
  • 6.5 By Country
    • 6.5.1 U.S. Market Size and Forecast
      • 6.5.1.1 By offering
      • 6.5.1.2 By technology
        • 6.5.1.2.1 IVD market for clinical chemistry, by type
        • 6.5.1.2.2 IVD market for immunochemistry, by type
        • 6.5.1.2.3 IVD market for molecular diagnostics, by type
        • 6.5.1.2.4 IVD market for hematology, by type
      • 6.5.1.3 By application
      • 6.5.1.4 By end user
    • 6.5.2 Canada Market Size and Forecast
      • 6.5.2.1 By offering
      • 6.5.2.2 By technology
        • 6.5.2.2.1 IVD market for clinical chemistry, by type
        • 6.5.2.2.2 IVD market for immunochemistry, by type
        • 6.5.2.2.3 IVD market for molecular diagnostics, by type
        • 6.5.2.2.4 IVD market for hematology, by type
      • 6.5.2.3 By application
      • 6.5.2.4 By end user

Chapter 7. Europe Market Size and Forecast

  • 7.1 By Offering
  • 7.2 By Technology
    • 7.2.1 IVD Market for Clinical Chemistry, by Type
    • 7.2.2 IVD Market for Immunochemistry, by Type
    • 7.2.3 IVD Market for Molecular Diagnostics, by Type
    • 7.2.4 IVD Market for Hematology, by Type
  • 7.3 By Application
  • 7.4 By End User
  • 7.5 By Country
    • 7.5.1 Germany Market Size and Forecast
      • 7.5.1.1 By offering
      • 7.5.1.2 By technology
        • 7.5.1.2.1 IVD market for clinical chemistry, by type
        • 7.5.1.2.2 IVD market for immunochemistry, by type
        • 7.5.1.2.3 IVD market for molecular diagnostics, by type
        • 7.5.1.2.4 IVD market for hematology, by type
      • 7.5.1.3 By application
      • 7.5.1.4 By end user
    • 7.5.2 France Market Size and Forecast
      • 7.5.2.1 By offering
      • 7.5.2.2 By technology
        • 7.5.2.2.1 IVD market for clinical chemistry, by type
        • 7.5.2.2.2 IVD market for immunochemistry, by type
        • 7.5.2.2.3 IVD market for molecular diagnostics, by type
        • 7.5.2.2.4 IVD market for hematology, by type
      • 7.5.2.3 By application
      • 7.5.2.4 By end user
    • 7.5.3 Italy Market Size and Forecast
      • 7.5.3.1 By offering
      • 7.5.3.2 By technology
        • 7.5.3.2.1 IVD market for clinical chemistry, by type
        • 7.5.3.2.2 IVD market for immunochemistry, by type
        • 7.5.3.2.3 IVD market for molecular diagnostics, by type
        • 7.5.3.2.4 IVD market for hematology, by type
      • 7.5.3.3 By application
      • 7.5.3.4 By end user
    • 7.5.4 Spain Market Size and Forecast
      • 7.5.4.1 By offering
      • 7.5.4.2 By technology
        • 7.5.4.2.1 IVD market for clinical chemistry, by type
        • 7.5.4.2.2 IVD market for immunochemistry, by type
        • 7.5.4.2.3 IVD market for molecular diagnostics, by type
        • 7.5.4.2.4 IVD market for hematology, by type
      • 7.5.4.3 By application
      • 7.5.4.4 By end user
    • 7.5.5 U.K. Market Size and Forecast
      • 7.5.5.1 By offering
      • 7.5.5.2 By technology
        • 7.5.5.2.1 IVD market for clinical chemistry, by type
        • 7.5.5.2.2 IVD market for immunochemistry, by type
        • 7.5.5.2.3 IVD market for molecular diagnostics, by type
        • 7.5.5.2.4 IVD market for hematology, by type
      • 7.5.5.3 By application
      • 7.5.5.4 By end user

Chapter 8. APAC Market Size and Forecast

  • 8.1 By offering
  • 8.2 By Technology
    • 8.2.1 IVD Market for Clinical Chemistry, by Type
    • 8.2.2 IVD Market for Immunochemistry, by Type
    • 8.2.3 IVD Market for Molecular Diagnostics, by Type
    • 8.2.4 IVD Market for Hematology, by Type
  • 8.3 By Application
  • 8.4 By End User
  • 8.5 By Country
    • 8.5.1 China Market Size and Forecast
      • 8.5.1.1 By offering
      • 8.5.1.2 By technology
        • 8.5.1.2.1 IVD market for clinical chemistry, by type
        • 8.5.1.2.2 IVD market for immunochemistry, by type
        • 8.5.1.2.3 IVD market for molecular diagnostics, by type
        • 8.5.1.2.4 IVD market for hematology, by type
      • 8.5.1.3 By application
      • 8.5.1.4 By end user
    • 8.5.2 Japan Market Size and Forecast
      • 8.5.2.1 By offering
      • 8.5.2.2 By technology
        • 8.5.2.2.1 IVD market for clinical chemistry, by type
        • 8.5.2.2.2 IVD market for immunochemistry, by type
        • 8.5.2.2.3 IVD market for molecular diagnostics, by type
        • 8.5.2.2.4 IVD market for hematology, by type
      • 8.5.2.3 By application
      • 8.5.2.4 By end user
    • 8.5.3 India Market Size and Forecast
      • 8.5.3.1 By offering
      • 8.5.3.2 By technology
        • 8.5.3.2.1 IVD market for clinical chemistry, by type
        • 8.5.3.2.2 IVD market for immunochemistry, by type
        • 8.5.3.2.3 IVD market for molecular diagnostics, by type
        • 8.5.3.2.4 IVD market for hematology, by type
      • 8.5.3.3 By application
      • 8.5.3.4 By end user

Chapter 9. LATAM Market Size and Forecast

  • 9.1 By offering
  • 9.2 By Technology
    • 9.2.1 IVD Market for Clinical Chemistry, by Type
    • 9.2.2 IVD Market for Immunochemistry, by Type
    • 9.2.3 IVD Market for Molecular Diagnostics, by Type
    • 9.2.4 IVD Market for Hematology, by Type
  • 9.3 By Application
  • 9.4 By End User
  • 9.5 By Country
    • 9.5.1 Brazil Market Size and Forecast
      • 9.5.1.1 By offering
      • 9.5.1.2 By technology
        • 9.5.1.2.1 IVD market for clinical chemistry, by type
        • 9.5.1.2.2 IVD market for immunochemistry, by type
        • 9.5.1.2.3 IVD market for molecular diagnostics, by type
        • 9.5.1.2.4 IVD market for hematology, by type
      • 9.5.1.3 By application
      • 9.5.1.4 By end user
    • 9.5.2 Mexico Market Size and Forecast
      • 9.5.2.1 By offering
      • 9.5.2.2 By technology
        • 9.5.2.2.1 IVD market for clinical chemistry, by type
        • 9.5.2.2.2 IVD market for immunochemistry, by type
        • 9.5.2.2.3 IVD market for molecular diagnostics, by type
        • 9.5.2.2.4 IVD market for hematology, by type
      • 9.5.2.3 By application
      • 9.5.2.4 By end user

Chapter 10. MEA Market Size and Forecast

  • 10.1 By offering
  • 10.2 By Technology
    • 10.2.1 IVD Market for Clinical Chemistry, by Type
    • 10.2.2 IVD Market for Immunochemistry, by Type
    • 10.2.3 IVD Market for Molecular Diagnostics, by Type
    • 10.2.4 IVD Market for Hematology, by Type
  • 10.3 By Application
  • 10.4 By End User
  • 10.5 By Country
    • 10.5.1 Saudi Arabia Market Size and Forecast
      • 10.5.1.1 By offering
      • 10.5.1.2 By technology
        • 10.5.1.2.1 IVD market for clinical chemistry, by type
        • 10.5.1.2.2 IVD market for immunochemistry, by type
        • 10.5.1.2.3 IVD market for molecular diagnostics, by type
        • 10.5.1.2.4 IVD market for hematology, by type
      • 10.5.1.3 By application
      • 10.5.1.4 By end user
    • 10.5.2 South Africa Market Size and Forecast
      • 10.5.2.1 By offering
      • 10.5.2.2 By technology
        • 10.5.2.2.1 IVD market for clinical chemistry, by type
        • 10.5.2.2.2 IVD market for immunochemistry, by type
        • 10.5.2.2.3 IVD market for molecular diagnostics, by type
        • 10.5.2.2.4 IVD market for hematology, by type
      • 10.5.2.3 By application
      • 10.5.2.4 By end user

Chapter 11. Competitive Landscape

  • 11.1 Global IVD Market Share of Key Players
  • 11.2 Strategic Developments of Key Players
    • 11.2.1 Product Launches and Approvals
    • 11.2.2 Mergers and Acquisitions
    • 11.2.3 Other Developments

Chapter 12. Company Profiles

  • 12.1 Thermo Fisher Scientific Inc.
    • 12.1.1 Business Overview
    • 12.1.2 Product and Service Offerings
    • 12.1.3 Key Financial Summary
  • 12.2 Danaher Corporation
    • 12.2.1 Business Overview
    • 12.2.2 Product and Service Offerings
    • 12.2.3 Key Financial Summary
  • 12.3 F. Hoffmann-La Roche Ltd.
    • 12.3.1 Business Overview
    • 12.3.2 Product and Service Offerings
    • 12.3.3 Key Financial Summary
  • 12.4 PerkinElmer Inc.
    • 12.4.1 Business Overview
    • 12.4.2 Product and Service Offerings
    • 12.4.3 Key Financial Summary
  • 12.5 Quidel Corporation
    • 12.5.1 Business Overview
    • 12.5.2 Product and Service Offerings
    • 12.5.3 Key Financial Summary
  • 12.6 OraSure Technologies Inc.
    • 12.6.1 Business Overview
    • 12.6.2 Product and Service Offerings
    • 12.6.3 Key Financial Summary
  • 12.7 Sysmex Corporation
    • 12.7.1 Business Overview
    • 12.7.2 Product and Service Offerings
    • 12.7.3 Key Financial Summary
  • 12.8 DIAGNOSTICA STAGO S.A.S
    • 12.8.1 Business Overview
    • 12.8.2 Product and Service Offerings
  • 12.9 Siemens AG
    • 12.9.1 Business Overview
    • 12.9.2 Product and Service Offerings
    • 12.9.3 Key Financial Summary
  • 12.10 Abbott Laboratories
    • 12.10.1 Business Overview
    • 12.10.2 Product and Service Offerings
    • 12.10.3 Key Financial Summary
  • 12.11 Becton, Dickinson and Company
    • 12.11.1 Business Overview
    • 12.11.2 Product and Service Offerings
    • 12.11.3 Key Financial Summary
  • 12.12 Hologic Inc.
    • 12.12.1 Business Overview
    • 12.12.2 Product and Service Offerings
    • 12.12.3 Key Financial Summary
  • 12.13 Sartorius Stedim Biotech S.A.
    • 12.13.1 Business Overview
    • 12.13.2 Product and Service Offerings
    • 12.13.3 Key Financial Summary
  • 12.14 Bio-Rad Laboratories Inc.
    • 12.14.1 Business Overview
    • 12.14.2 Product and Service Offerings
    • 12.14.3 Key Financial Summary
  • 12.15 bioMerieux S.A.
    • 12.15.1 Business Overview
    • 12.15.2 Product and Service Offerings
    • 12.15.3 Key Financial Summary

12.16 Trinity Biotech plc

    • 12.16.1 Business Overview
    • 12.16.2 Product and Service Offerings
    • 12.16.3 Key Financial Summary

12.17 Bio-Techne Corporation

    • 12.17.1 Business Overview
    • 12.17.2 Product and Service Offerings
    • 12.17.3 Key Financial Summary

12.18 DiaSorin S.p.A.

    • 12.18.1 Business Overview
    • 12.18.2 Product and Service Offerings
    • 12.18.3 Key Financial Summary

12.19 Ortho-Clinical Diagnostics Inc.

    • 12.19.1 Business Overview
    • 12.19.2 Product and Service Offerings

12.20 Grifols S.A.

    • 12.20.1 Business Overview
    • 12.20.2 Product and Service Offerings
    • 12.20.3 Key Financial Summary

Chapter 13. Appendix

  • 13.1 Abbreviations
  • 13.2 Sources and References
  • 13.3 Related Reports

LIST OF FIGURES

  • FIG 1 RESEARCH SCOPE
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY REGION
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT
  • FIG 6 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
  • FIG 7 DATA TRIANGULATION APPROACH
  • FIG 8 GLOBAL IVD MARKET SUMMARY
  • FIG 9 BARGAINING POWER OF BUYERS
  • FIG 10 BARGAINING POWER OF SUPPLIERS
  • FIG 11 INTENSITY OF RIVALRY
  • FIG 12 THREAT OF NEW ENTRANTS
  • FIG 13 THREAT OF SUBSTITUTES
  • FIG 14 GLOBAL IVD MARKET SNAPSHOT (2019)
  • FIG 15 GLOBAL IVD MARKET, BY OFFERING, $M (2014-2030)
  • FIG 16 GLOBAL IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
  • FIG 17 GLOBAL IVD MARKET, BY APPLICATION, $M (2014-2030)
  • FIG 18 GLOBAL IVD MARKET, BY END USER, $M (2014-2030)
  • FIG 19 GLOBAL IVD MARKET, BY REGION, $M (2014-2030)
  • FIG 20 NORTH AMERICA IVD MARKET SNAPSHOT
  • FIG 21 NORTH AMERICA IVD MARKET, BY OFFERING, $M (2014-2030)
  • FIG 22 NORTH AMERICA IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
  • FIG 23 NORTH AMERICA IVD MARKET, BY APPLICATION, $M (2014-2030)
  • FIG 24 NORTH AMERICA IVD MARKET, BY END USER, $M (2014-2030)
  • FIG 25 NORTH AMERICA IVD MARKET, BY COUNTRY, $M (2014-2030)
  • FIG 26 EUROPE IVD MARKET SNAPSHOT
  • FIG 27 EUROPE IVD MARKET, BY OFFERING, $M (2014-2030)
  • FIG 28 EUROPE IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
  • FIG 29 EUROPE IVD MARKET, BY APPLICATION, $M (2014-2030)
  • FIG 30 EUROPE IVD MARKET, BY END USER, $M (2014-2030)
  • FIG 31 EUROPE IVD MARKET, BY COUNTRY, $M (2014-2030)
  • FIG 32 APAC IVD MARKET SNAPSHOT
  • FIG 33 APAC IVD MARKET, BY OFFERING, $M (2014-2030)
  • FIG 34 APAC IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
  • FIG 35 APAC IVD MARKET, BY APPLICATION, $M (2014-2030)
  • FIG 36 APAC IVD MARKET, BY END USER, $M (2014-2030)
  • FIG 37 APAC IVD MARKET, BY COUNTRY, $M (2014-2030)
  • FIG 38 LATAM IVD MARKET SNAPSHOT
  • FIG 39 LATAM IVD MARKET, BY OFFERING, $M (2014-2030)
  • FIG 40 LATAM IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
  • FIG 41 LATAM IVD MARKET, BY APPLICATION, $M (2014-2030)
  • FIG 42 LATAM IVD MARKET, BY END USER, $M (2014-2030)
  • FIG 43 LATAM IVD MARKET, BY COUNTRY, $M (2014-2030)
  • FIG 44 MEA IVD MARKET SNAPSHOT
  • FIG 45 MEA IVD MARKET, BY OFFERING, $M (2014-2030)
  • FIG 46 MEA IVD MARKET, BY TECHNOLOGY, $M (2014-2030)
  • FIG 47 MEA IVD MARKET, BY APPLICATION, $M (2014-2030)
  • FIG 48 MEA IVD MARKET, BY END USER, $M (2014-2030)
  • FIG 49 MEA IVD MARKET, BY COUNTRY, $M (2014-2030)
  • FIG 50 GLOBAL IVD MARKET SHARE OF KEY PLAYERS, 2019
  • FIG 51 THERMO FISHER SCIENTIFIC INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 52 DANAHER CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 53 F. HOFFMANN-LA ROCHE LTD. - REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2019)
  • FIG 54 PERKINELMER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 55 QUIDEL CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 56 ORASURE TECHNOLOGIES INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 57 SYSMEX CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 58 SIEMENS AG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 59 ABBOTT LABORATORIES - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 60 BECTON, DICKINSON AND COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 61 HOLOGIC INC. - REVENUE SPLIT BY PRODUCT SEGMENT AND GEOGRAPHY (2019)
  • FIG 62 SARTORIUS STEDIM BIOTECH S.A. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 63 BIO-RAD LABORATORIES INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 64 BIOMERIEUX S.A. - REVENUE SPLIT BY APPLICATION AND GEOGRAPHY (2018)
  • FIG 65 TRINITY BIOTECH PLC. - REVENUE SPLIT BY SEGMENT (2018)
  • FIG 66 BIO-TECHNE CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
  • FIG 67 DIASORIN S.P.A. - REVENUE SPLIT BY TECHNOLOGY AND GEOGRAPHY (2018)
  • FIG 68 GRIFOLS S.A. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)